In a randomized, placebo-controlled trial that enrolled patients with chronic kidney disease stages 3 and 4, sodium bicarbonate did not significant affect sit-to-stand time or bone mineral density.
A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
Chronic kidney disease (CKD) is a commonly diagnosed condition, affecting approximately 30 million adults in the United States.1 CKD refers to a diverse group of pathologies that result in kidney function decline for at least 3 months.2,3 Kidney disease etiologies are generally classified into 3 categories: prerenal, intrinsic renal, and postrenal. Prerenal disease is marked…
A study of patients with chronic kidney disease found that regular and occasional binge drinkers had double the risk of disease progression compared with non-drinkers.
Increasing levels of fibroblast growth factor 23 in patients with chronic kidney disease are independently associated with an increased risk of requiring maintenance dialysis or a kidney transplant, a study found.
Compared with never-drinkers, individuals who consumed 2 to 7, 8 to 14, and 15 or more drinks per week had significant 12%, 20%, 29%, and 23% decreased risks of incident chronic kidney disease, respectively, in adjusted analyses, according to a new report.
The FDA has accepted for review the New Drug Application (NDA) for veverimer (TRC101; Tricida) for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).
